Renalytix inks partnership with Singing River Health System
10th Jan 2022 12:33
(Sharecast News) - Renalytix announced a partnership with Singing River Health System to deploy 'KidneyIntelX' informed care management on Monday, to improve kidney health in individuals with type-2 diabetes and early-stage chronic kidney disease.
Read moreRenalytix inks partnership with the American Diabetes Association
4th Jan 2022 11:18
(Sharecast News) - Renalytix announced a joint programme with the American Diabetes Association (ADA) on Tuesday, to improve overall kidney health in patients with type-2 diabetes (T2D) in the United States.
Read moreLosses widen as Renalytix achieves revenue in first quarter
7th Dec 2021 10:05
(Sharecast News) - Artificial intelligence (AI) diagnostics company Renalytix reported first quarter revenue of $0.5m on Tuesday, up from nil at the same time last year.
Read moreRenalytix inks partnership with US healthcare provider St Joseph's
9th Nov 2021 10:55
(Sharecast News) - Renalytix announced a partnership with St Joseph's Health on Tuesday, to implement an advanced clinical care model designed to improve kidney health in patients with type-2 diabetes and early-stage chronic kidney disease.
Read moreRenalytix appoints VP to oversee Veterans Health rollout
7th Oct 2021 10:59
(Sharecast News) - Renalytix announced the expansion of its commercial strategy to address early-stage kidney disease in the United States Veterans Health Administration (VA) patient population on Thursday, with the appointment of Jed Fulk to the position of vice-president of sales to government accounts.
Read moreRenalytix appoints Ann Berman to board
28th Jul 2021 11:19
(Sharecast News) - Renalytix announced the appointment of Ann Berman to its board on Wednesday, as chair of its audit committee and a member of the nomination committee.
Read moreRenalytix upbeat on new KidneyIntelX data
28th Jun 2021 08:36
(Sharecast News) - Renalytix announced new data demonstrating that its 'KidneyIntelX' product can be effective at monitoring therapeutic response and improvements in kidney health over time, in adults with type-2 diabetes.
Read moreDirector dealings: Renalytix AI interim chairman makes share sale
22nd Jun 2021 16:05
(Sharecast News) - Renalytix AI revealed on Tuesday that interim chairman Christopher Mills had disposed of 17,000 ordinary shares in the AIM-listed artificial intelligence firm.
Read moreNet losses balloon at Renalytix AI in third quarter
15th Jun 2021 09:55
(Sharecast News) - Renalytix AI recorded $0.6m (£0.43m) of services revenue in its third quarter, it said on Tuesday, related to work performed for Mount Sinai, and $0.1m of testing revenue.
Read moreRenalytix AI upbeat on results of utility study
3rd Jun 2021 10:37
(Sharecast News) - Renalytix AI announced results from a new utility study on Thursday, which confirmed the importance of risk assessment testing in addressing treatment ambiguity in the early stages of diabetic kidney disease (DKD).
Read moreRenalytix AI enters new partnership in America's 'diabetes belt'
19th May 2021 10:06
(Sharecast News) - Renalytix AI announced a partnership with Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine on Wednesday, to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations.
Read moreRenalytix AI wins 10-year US government contract
22nd Apr 2021 16:03
(Sharecast News) - Renalytix AI announced on Thursday that the United States government has granted it a 10-year 'Governmentwide Acquisition Contract' (GWAC) to provide 'KidneyIntelX' early-stage kidney disease bioprognostic testing services.
Read moreRenalytix AI upbeat on new study findings
20th Apr 2021 13:48
(Sharecast News) - Renalytix AI announced the findings of a new study in which the commercially-available 'KidneyIntelX' test accurately predicted the progression of diabetic kidney disease (DKD) in a multinational cohort from the CANagliflozin CardioVAScular Assessment Study (CANVAS), with early-stage DKD.
Read moreRenalytix AI enters option agreement with Joslin Diabetes Center
14th Apr 2021 09:02
(Sharecast News) - Renalytix AI has entered into an exclusive option agreement with Joslin Diabetes Center for patent filings on additional novel biomarkers in kidney disease, it announced on Wednesday, for development and deployment in the 'KidneyIntelX' in vitro prognostic platform.
Read moreRenalytix AI upbeat on KidneyIntelX study results
8th Apr 2021 08:20
(Sharecast News) - Renalytix AI announced findings presented in a late-breaking presentation at the National Kidney Foundation's 2021 Spring Clinical Meetings on Thursday, titled 'Clinical Utility of a New Prognostic Test to Predict the Risk of Kidney Function Decline in Diabetic Kidney Disease Patients'.
Read more